CA2438032A1 - Derives de benzothiazole et compositions et utilisations connexes - Google Patents

Derives de benzothiazole et compositions et utilisations connexes Download PDF

Info

Publication number
CA2438032A1
CA2438032A1 CA002438032A CA2438032A CA2438032A1 CA 2438032 A1 CA2438032 A1 CA 2438032A1 CA 002438032 A CA002438032 A CA 002438032A CA 2438032 A CA2438032 A CA 2438032A CA 2438032 A1 CA2438032 A1 CA 2438032A1
Authority
CA
Canada
Prior art keywords
compound
hydrogen
alkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002438032A
Other languages
English (en)
Other versions
CA2438032C (fr
Inventor
William E. Klunk
Chester A. Mathis, Jr.
Yanming Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/388,173 external-priority patent/US7270800B2/en
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Priority to CA2438032A priority Critical patent/CA2438032C/fr
Priority to US10/645,847 priority patent/US20050043523A1/en
Priority claimed from US10/645,847 external-priority patent/US20050043523A1/en
Priority to PCT/US2004/007797 priority patent/WO2004083195A1/fr
Publication of CA2438032A1 publication Critical patent/CA2438032A1/fr
Application granted granted Critical
Publication of CA2438032C publication Critical patent/CA2438032C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2438032A 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes Expired - Lifetime CA2438032C (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2438032A CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses
PCT/US2004/007797 WO2004083195A1 (fr) 2003-03-14 2004-03-15 Composes derives de benzothiazole, compositions et utilisations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/388,173 US7270800B2 (en) 2000-08-24 2003-03-14 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CA2438032A CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses

Publications (2)

Publication Number Publication Date
CA2438032A1 true CA2438032A1 (fr) 2005-02-22
CA2438032C CA2438032C (fr) 2013-05-07

Family

ID=34426453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2438032A Expired - Lifetime CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes

Country Status (2)

Country Link
CA (1) CA2438032C (fr)
WO (1) WO2004083195A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2510455C (fr) 2002-12-19 2013-03-12 The Scripps Research Institute Compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
WO2005118511A2 (fr) 2004-05-20 2005-12-15 The Scripps Research Institute Composes, compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
WO2006014381A2 (fr) 2004-07-02 2006-02-09 University Of Pittsburgh Imagerie d'amyloides comme marqueur auxiliaire pour l'efficacite de therapies anti-amyloides
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (fr) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Procedes pour le traitement de l'hepatite c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275182A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating Hepatitis C
GB0516564D0 (en) 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
US20080305040A1 (en) * 2005-09-16 2008-12-11 University Of Pittsburgh In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein
ATE533485T1 (de) † 2005-10-31 2011-12-15 Merck Sharp & Dohme Cetp-inhibitoren
WO2007063946A1 (fr) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. Diagnostic et remede pour une maladie provoquee par l’aggregation et/ou le depot d’amyloide
EP1971584A2 (fr) * 2005-12-01 2008-09-24 University of Pittsburgh - Of the Commonwealth System of Higher Education Composes de benzothiazole marques aux isotopes utiles en tant qu'agents d'imagerie pour des proteines amyloidogeniques
GB0525949D0 (en) 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
TW201018678A (en) * 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
US20100098631A1 (en) * 2007-03-06 2010-04-22 Astrazeneca Ab Novel-2-Heteroaryl Substituted Indoles 695
US7858803B2 (en) * 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
AU2008292201B2 (en) * 2007-08-30 2014-09-04 Ge Healthcare Limited Radiopharmaceutical composition
ITMC20080089A1 (it) * 2008-05-23 2008-08-22 Sparkle S R L Sintesi chimica di i-124[6-oh-bta-1-3'-i] iodine-124[2-(3'-iodo-4'-methylaminophenyl)-6-hydroxy-benzothialzole] per indagini pet e radioterapia.
EP2300481B1 (fr) 2008-05-30 2015-09-30 Merck Sharp & Dohme Corp. Nouveaux azabenzoxazoles substitués
EP2338059B1 (fr) 2008-09-23 2015-04-08 WisTa Laboratories Ltd. Ligands pour molécules de la protéine tau agglomérées
US20110212031A1 (en) * 2008-10-31 2011-09-01 Cyrille Sur Novel substituted azabenzoxazoles
EP2755961A1 (fr) 2011-09-16 2014-07-23 Pfizer Inc Formes solides d'un inhibiteur de la dissociation de dérivés de transthyrétine
WO2014032732A1 (fr) 2012-08-28 2014-03-06 Eberhard Karls Universität Tübingen Medizinische Fakultät Benzoxazine halogénée et son utilisation
CN105579453B (zh) * 2013-09-26 2017-12-22 豪夫迈·罗氏有限公司 作为成像工具的咪唑并[1，2‑a]吡啶‑7‑胺类
WO2015051188A1 (fr) 2013-10-02 2015-04-09 Washington University Molécules hétérocycliques pour l'imagerie biomédicale et leurs applications thérapeutiques
SI3186233T1 (sl) 2014-08-29 2022-04-29 Chdi Foundation, Inc. Sonde za slikanje proteina huntingtina
WO2016033460A1 (fr) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Sondes d'imagerie de la protéine huntingtine
JP6485914B2 (ja) 2015-10-28 2019-03-20 日本メジフィジックス株式会社 フルテメタモルの製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
RU2324686C2 (ru) * 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
JP4317955B2 (ja) * 2001-04-23 2009-08-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア アミロイド斑凝集阻害剤および診断用造影剤

Also Published As

Publication number Publication date
WO2004083195A1 (fr) 2004-09-30
CA2438032C (fr) 2013-05-07

Similar Documents

Publication Publication Date Title
CA2438032C (fr) Derives de benzothiazole et compositions et utilisations connexes
US9833458B2 (en) Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US9134328B2 (en) Methods of using benzothiazole derivative compounds and compositions
AU2011200667B2 (en) Benzothiazole derivative compounds, compositions and uses
US20120263646A1 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AU2001286702A1 (en) Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
US20050043523A1 (en) Benzothiazole derivative compounds, compositions and uses
WO2023098622A1 (fr) LIGAND DE LIAISON À PETITE MOLÉCULE D'AGRÉGAT D'α-SYNUCLÉINE, PROCÉDÉ DE PRÉPARATION ET UTILISATION ASSOCIÉS

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230822